Ignite Creation Date:
2025-12-24 @ 1:36 PM
Ignite Modification Date:
2026-04-13 @ 10:16 PM
Study NCT ID:
NCT02206295
Status:
COMPLETED
Last Update Posted:
2025-02-03
First Post:
2014-07-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg
Sponsor:
Actelion
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-09
Start Date Type:
None
Primary Completion Date:
2012-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2012-12
Completion Date Type:
ACTUAL
First Submit Date:
2014-07-30
First Submit QC Date:
None
Study First Post Date:
2014-08-01
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-01-31
Last Update Post Date:
2025-02-03
Last Update Post Date Type:
ACTUAL